Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
Globenewswire·2025-04-28 11:00
FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models AVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025) Avacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotox ...